Lundbeck beats forecasts considerably in Q4

In spite of Lundbeck's key product sales retreating the last months of 2020, the pharmaceutical company has profits to show, which vastly exceed the same post from the comparable period last year – and analyst forecasts. The company expects declining revenue in the new year.

Photo: Jens Dresling

The Covid-19-induced weakening US dollar and competitive market for pharmaceutical producers in 2020's fall and winter have made their mark on Lundbeck's finances.

Sales relating to the pharmaceutical firm's five key products targeting psychiatric illnesses took a dive in the last quarter of the year – from DKK 2.850bn (USD 459.4m) to DKK 2.691bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs